chose 10 µg/dL as an initial screening level for lead in children's blood.
 PUBLIC HEALTH MATTERS 
The US Centers for Disease Control and Prevention (CDC) in 1991 chose 10 µg/dL as an initial screening level for lead in children's blood.
Current data on health risks and intervention options do not support generally lowering that level, but federal lead poisoning prevention efforts can be improved by revising the follow-up testing schedule for infants aged 1 year or less with blood lead levels of 5 µg/dL or higher; universal education about lead exposure risks; universal administration of improved, locally validated risk-screening questionnaires; enhanced compliance with targeted screening recommendations and federal health program requirements; and development by regulatory agencies of primary prevention criteria that do not use the CDC's intervention level as a target "safe" lead exposure. teristics of 1-to 5-year-old children with BLLs of at least 5 µg/dL but less than 10 µg/ dL. 4 In this article, I investigate whether data or policy considerations support lowering the childhood blood lead screening level.
BACKGROUND
There is extensive literature on the health impacts of lead exposure in early childhood. [5] [6] [7] At high doses, these impacts can include damage to the nervous, hematopoietic, endocrine, and renal systems. At lower exposures, lead has been associated with adverse cognitive and neurobehavioral impacts. Epidemiological data on the adverse health outcomes of lead exposure are supported by research on mechanisms of lead toxicity and by animal studies, reviewed by the Agency for Toxic Substances and Disease Registry. 7 Children in the United States have been exposed to lead from many sources, in particular lead used as an additive to gasoline 8 and as a component of paint. 9, 10 Although each of these uses is now banned in the United States, children continue to be exposed to lead, primarily as a result of the presence in housing of lead-contaminated paint and resulting dust, soil, and chips. [11] [12] [13] [14] The high prevalence over the 20th century of clinical and subclinical lead intoxication among US children is well documented. 5, 15 As exposures have been reduced, the levels and prevalence of childhood lead intoxication have also declined. [16] [17] [18] [19] [20] Over the 6-year period of NHANES III (1988) (1989) (1990) (1991) (1992) (1993) (1994) , there was a 48.4% decline in the percentage of children with BLLs defined as elevated: during phase 1 (1988) (1989) (1990) (1991) , 8 .9% of 1-to 5-year-olds had BLLs of 10 µg/dL or higher, while during phase 2 (1991-1994), 4.4% of 1-to 5-year-olds (890 000) had BLLs of 10 µg/dL or higher. 18 Much higher levels of lead poisoning have consistently been found among urban, lower-income, and African American children living in older housing in the Northeast and Midwest. 16, 17 Mean BLLs in these higher-risk populations have declined over time 21 but remain elevated in some locations and among some populations.
14 Medicaid eligibility is a strong predictor of lead poisoning risk. NHANES III phase 2 data (1991) (1992) (1993) (1994) showed that the prevalence of BLLs of 10 µg/dL or higher among 1-to 5-year-olds whose families participated in Medicaid was, at 9%, 3 times higher than the prevalence among non-Medicaid-enrolled children. 22 Sixty percent of 1-to 5-year-olds with BLLs of 10 µg/dL or higher were Medicaid participants, and 83% of 1-to 5-year-olds with BLLs of 20 µg/dL or higher were Medicaid participants.
22,23
Housing age, condition, and location are also important risk factors. 23 The risk posed by older housing (predating 1946) is higher for lower-income children. 18 In some older communities, lead poisoning is endemic. For example, a cross-sectional analysis of children in Illinois aged birth to 6 years for the years 1993 to 1997 showed no decline over that time in the number of children with BLLs of either 15 µg/dL or higher or 45 µg/dL or higher, in either the city of Chicago or the state as a whole. 24 While only 43% of the Chicago children lived within zip codes identified as being at high risk for lead, 99% of the hospitalizations for lead poisoning occurred among those children. 24 The US Centers for Disease Control and Prevention (CDC) has since 1970 set tiered screening and intervention levels for childhood lead poisoning. The purpose of these levels is to guide federal, state, and local health departments and individual pediatricians in identifying and responding appropriately to lead-exposed children. 1 No law requires development of the intervention levels, and criteria for setting and changing them are not well defined. They are set forth in CDC guidance documents that are implemented through conditions on funding to government and individual providers. The initial, or threshold, intervention level (referred to here as "the intervention level"), which was originally set at 40 µg/dL, was most recently lowered from 25 µg/dL to 10 µg/dL in 1991. 
 PUBLIC HEALTH MATTERS 
The 1997 guidance document recommends targeting blood lead screening and interventions to high-risk areas. 25 State public health officials receiving lead poisoning prevention grants must develop statewide plans for either performing universal screening or requiring screening for (1) higher-risk areas within the state identified through housing stock age or a prevalence of BLLs of 10 µg/dL or higher; (2) children who receive services from public assistance programs such as Medicaid; and (3) children whose parents or guardians provide responses to a personal risk questionnaire that indicate elevated risk of lead exposure, or who lack sufficient knowledge to answer a personal risk questionnaire. 25 To develop such a plan, the guidance document recommends that states set up advisory committees, assess lead exposure and screening capacity, determine boundaries of targeted areas, decide on appropriate screening requirements, and write and implement plans with respect to areas with universal screening and with targeted screening. 25 Investigations by the US General Accounting Office and the CDC have reported that throughout federally funded health programs, lead screening requirements are not satisfied. 23 The majority of children overall and within higher-risk subpopulations had BLLs of less than 10 µg/dL. 4 These data suggest that demographic and socioeconomic factors that characterize children with the highest levels of lead intoxication are also associated with children with lower levels of measurable blood lead. They also suggest that many children, even those considered to be in the lowest-risk groups, are exposed to some amounts of environmental lead. Sources of lead exposure other than those associated with residential paint may include drinking water (contaminated during delivery) 13 ; glazing on certain imported pottery and ceramics 29 ; certain imported foods 30 ; exposure to aging buildings (especially schools) that are not the primary residence of the child but within which the child spends significant amounts of time; soil contamination not attributed to lead-based paint 17 ; and pre-or perinatal exposure to maternal lead stores from past and current exposures.
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The risk of lead poisoning from many such exposures can be expected to diminish over time as a result of intentional and unintentional measures such as enforcement of lead prohibitions in consumer protection and public housing programs, voluntary lead abatement by private homeowners, replacement of water distribution lines, and replacement or renovation of housing and public buildings. Further research into individual children's cumulative exposure would be useful in explaining the continued prevalence of measurable levels of lead in children's blood.
Health Outcomes at BLLs of Less Than 10 µg/dL
Research on the adverse neurocognitive and other health impacts of childhood lead poisoning published since the CDC set the intervention level at 10 µg/dL in 1991 has included (1) follow-up analyses of cohort studies begun in the early 1980s in the United States and internationally (e.g., Tong et al. 34, 35 and Wasserman et al. 36 ) and more recent cohort studies conducted in Mexico 37 However, there is still substantial uncertainty with respect to health outcomes of childhood lead exposure resulting in BLLs below 10 µg/dL. There has been little research on health outcomes within populations of young children with BLLs below 10 µg/dL, and some investigators have questioned whether discerning neurocognitive impacts at such BLLs is feasible with current epidemiological and statistical methods. 48 Individual studies associating BLLs below 10 µg/dL with adverse cognitive impacts must be interpreted carefully in light of what is known about the significance of the timing within the lives of the study populations of exposure and outcome measurements; the importance of controlling for confounding and effectmodifying variables such as socioeconomic status, maternal education, and the quality of a child's home environment; uncertainties associated with various exposure and outcome measurements; and methodological limitations. 34, [49] [50] [51] As methods of measuring both lead exposure and cognitive development become more sensitive, subtle adverse impacts of very low levels of lead exposure may become better quantifiable, and it is important to continue this research. Continued in vivo and in vitro research will also be critical. 
IMPACT OF LOWERING THE CDC'S INTERVENTION LEVEL
Given that there is no naturally occurring level of lead in the human body, 5, 52 precautionary concerns might support lowering the intervention level pending further research if it could be demonstrated that lowering the level would benefit the target population at an acceptable cost or burden, factoring in the invasiveness of the screening methodology, the risk and discomfort to the individual patient, and the precision and validity of the test. 53 While capillary and venous blood lead measurements can produce satisfactorily precise and reliable data on a child's blood lead at the time of measurement, 54 most laboratories operate at a level in which samples in the 10-to 19-µg/dL range produce results within 4 µg/dL (95% confidence interval) of the true BLL. 55 Validity and precision decrease as the lead concentration in the blood decreases. Even if the test were shown to present minimal risk and discomfort at sufficient validity and precision, there is no clear benefit to most children of screening to detect BLLs of less than 10 µg/dL (an exception, discussed below, is children aged 12 months or younger, who should be identified for short-term follow-up screening if their BLL is 5 µg/dL or higher). Protecting children with BLLs of at least 5 µg/dL but less than 10 µg/dL would be the primary aim of lowering the intervention level from 10 µg/dL to 5 µg/dL, but for the most part screening would not benefit such children. Table 2 sets out the current intervention guidelines tied to children's BLLs. If the intervention level were lowered, the most likely change to these guidelines would be that interventions recommended for children with BLLs of 10 µg/dL to 14 µg/dL would now be recommended for children with BLLs of 5 µg/dL to 14 µg/dL. Thus, children with screening BLLs in this range would have diagnostic venipuncture within 3 months as well as family lead education, follow-up testing, and possible referral for social services. With respect to family lead education, providing basic information to all parents or guardians of pediatric patients about childhood lead poisoning exposure risk was suggested when the 1997 guidance was written, 27 is supported by the American Academy of Pediatrics (AAP), 56 Because of the relatively high proportion of children with BLLs of 5 µg/dL or higher, lowering the intervention level would likely result in a return to universal screening requirements. As a result, the change would result in the administration of blood tests to all 1-to 5-year-olds, even though at least 75% of them have BLLs of less than 5 µg/dL and thus would not benefit from the screening. National, universal screening would substantially raise the cost of case identification of children with elevated BLLs. On a much smaller scale, for example, the cost per case identification via universal screening among children aged 6 months to 6 years in a lowprevalence community in Denver, Colo (2.9% with BLLs ≥10 µg/dL, 0.3% with BLLs ≥20 µg/dL) was $463 for children with BLLs of 10 µg/dL or higher, $1713 for children with BLLs of 15 µg/dL or higher, and $4925 for children with BLLs of 20 µg/dL or higher, without factoring in staff time for phlebotomy  PUBLIC HEALTH MATTERS  or time for administration and review of the screening risk questionnaire. 60 Lowering the intervention level is likely to prove disadvantageous to the children with BLLs of 10 µg/dL or higher. First, while a return to universal screening, if fully implemented, would result in the discovery of children with elevated BLLs who would be missed by targeted screening, a risk-screening questionnaire, or both, it seems unlikely that there would be better compliance with the universal screening requirement than was prevalent between 1991 and 1997. Reasons given by physicians for failure to screen in the past included cost, futility where no interventions were available, lack of certainty in the health risks, and low population prevalence of elevated BLLs. 2, 23, 28, 52, 54, 58, [61] [62] [63] [64] [65] Second, although lowering the intervention level and consequently identifying roughly a fourth of US children as at risk could lead to an increase in public awareness of the problem of lead poisoning and possibly more funding, most of the available funds would probably be spent to screen the blood of millions of children with minimal or no exposure to lead and diverted from the predominantly poor and African American children who are most at risk. Such an allocation of resources would be contrary to federal priorities with respect to children's health, disproportionate health burdens, environmental justice, and lead poisoning prevention. 14, 25, [66] [67] [68] 
RECOMMENDATIONS
Although an across-the-board lowering of the intervention level is not warranted at this time, a number of changes in the approach and implementation of the 1997 guidance are recommended. These changes are intended to prioritize eliminating childhood BLLs of 10 µg/dL and higher, in keeping with federal policy. 14, 68 However, it is likely that improved implementation of the 1997 guidance would also protect children with BLLs of less than 10 µg/dL. For example, universal education about lead hazards might stimulate some prevention activities on the part of parents and guardians. In addition, abatement actions in response to communitywide or targeted interventions and incentives, or to the discovery of 1 or more children with BLLs of 10 µg/dL or higher, could reduce the exposure of other children living in that same environment currently and in the future. Brown and colleagues found that effective enforcement of state lead poisoning prevention laws significantly lowered the risk of a BLL of 10 µg/dL or higher for a child living in housing in which a child previously was found with a BLL of 25 µg/dL or higher.
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Revise Follow-Up Testing Schedule for Infants Aged 1 Year or Younger With BLLs of 5 µg/dL or Higher
The AAP, in its 1998 policy statement on screening for elevated BLLs, recommends that pediatricians begin lead screening infants at 9 to 12 months and that screening "be considered again at ~24 months of age when BLLs peak." 56 The 1997 guidance likewise recommends targeted screening at ages 1 and 2. 25 The CDC's recommendation should be revised to require that children aged 1 year or younger who are found to have BLLs of 5 µg/dL or higher be rescreened within 3 to 6 months. BLLs have been shown to rise from between birth and 2 years and peak between 18 and 24 months 70,71 as children become more mobile and eat more with their hands. The likelihood that a 1-year-old with a BLL of 5 µg/dL or higher will become a 2-yearold with a BLL of 10 µg/dL or higher will depend on individual risk factors, but the probability is sufficiently high that a full year should not pass before retesting, as recommended by the 1997 guidance and by the AAP. Data reported by the CDC indicated that the prevalence of BLLs of 10 µg/dL or higher among 1-year-olds in high-risk areas of Chicago in 1997 was 17%, while among 2-year-olds it was 29%. 28 Thirty-nine percent of the children with BLLs of less than 10 µg/ dL at the age of 1 year during 1995 and 1996 were retested 1 year later; of those, 21% had developed BLLs of 10 µg/dL or higher.
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Make Parent/Guardian Education Universal
Studies do not provide strong support for the usefulness of education interventions alone in preventing or reducing elevated BLLs. 27, 54, 72, 73 However, because parents and guardians need to be educated about exposure risks in order to give informed consent for a blood test or to complete a riskscreening questionnaire, and because such education would enhance the value of the risk-screening questionnaire, it should not depend on the outcome of a screening blood test. The AAP recommends that pediatricians provide guidance to parents of all infants and toddlers on risk factors for lead exposure and specific prevention strategies tailored to the family and community 56 ; the 1997 guidance document is less explicit on the need for exposure risk education in advance of completing the basic personal risk questionnaire, but that is the focus of the questionnaire.
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In keeping with the AAP recommendations and the 1997 guidance document, 25, 56 pediatricians and public health workers should provide more detailed, case-specific assistance in identifying and reducing actual exposures of children discovered to have elevated BLLs.
Improve the Risk-Screening Questionnaire
The risk-screening questionnaire is critical to finding children who are not subject to targeted screening owing to risk factors such as Medicaid eligibility, but who nonetheless are at risk-for example, owing to the age or condition of their child care provider's facilities or because they live in older housing undergoing renovation. 11 Analyses of the questionnaire in use from 1991 through 1997 (when universal screening was required and the questionnaire was geared toward frequency of testing rather than necessity for testing) indicated that the questionnaire was insufficient to identify children with elevated BLLs. 60, [74] [75] [76] Suggestions for improving the questionnaire include adding questions that will identify children who have either emigrated to the United States with their families or been adopted and who may be at increased risk owing to either pre-or postimmigration exposure 56, [77] [78] [79] and targeting children who may be exposed to lead-containing folk remedies.
Other at-risk children who could be identified through a well-developed questionnaire include those whose parents are exposed to lead through occupation or hobby, 77 
Stop Use of the CDC Intervention Level in Establishing Primary Prevention Goals
Although the CDC's intervention level is not a statement concerning the level of childhood blood lead considered "safe" or "acceptable," it has been interpreted as such by the general public (e.g., see Lambrecht 85 ) and by federal regulatory agencies. For example, the goal of the EPA's National Ambient Air Quality Standard for lead, which was set in 1976, was to lower the BLL of 95% of the population to less than 30 µg/dL, the then-applicable CDC intervention level. 86, 87 More recently, standards for cleanup of leadbased paint hazards under section 403 of the Toxic Substances Control Act were set to achieve the current intervention level of 10 µg/dL. 88 Setting lead cleanup and abatement targets to achieve postabatement exposures of no more than 10 µg/dL does not adequately protect children's health and may in some cases be contrary to federal environmental health laws and policies. In setting enforceable air quality standards under the Clean Air Act (National Ambient Air Quality Standard), for example, the EPA must identify the standards regarding the maximum level of the contaminant "which in the judgment of the Administrator [of EPA], based on criteria and allowing an adequate margin of safety, are requisite to protect the public health," without regard to cost or technologic feasibility, and must review the standards with the aid of an independent scientific review committee every 5 years. 89 The EPA has not developed a reference dose for inorganic lead, as it has for other neurotoxins about which much less information is available. A reference dose is defined as "an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime." 90 The EPA has attributed this inaction to lack of evidence of a threshold for noncarcinogenic toxic effects, particularly neurobehavioral effects in children, 7, 90 and it has not attempted to develop a reference dose using alternative methods, such as the benchmark dose approach 91 used in setting a reference dose for mercury, 92 that do not require identification of a lowest adverse effect level. Paradoxically, the use of the CDC's intervention level as a de facto reference dose results in the use of an exposure target for lead that is degrees of magnitude higher than it would be if set by such risk assessment methodologies. As a practical matter, developing a reference dose could result in setting lead exposure targets at-and, for some vulnerable populations, below-actual current exposures, and meeting such targets may prove difficult or even, in some situations, impossible. Yet simply using the screening and intervention level as a default exposure goal is not the answer to these complex questions. The federal government should reexamine its lead exposure reduction targets and redefine them as necessary, within the parameters specified by the relevant governing statutes and regulations, to fully protect children's health. In setting such standards, the adverse health impacts of lead other than neurocognitive outcomes must also be considered, including impacts on physical growth (stature and head circumference 93, 43, 39 ); impacts on hearing, 94, 95 behavior and delinquency, 96 and heme biosynthesis 42 ; and outcomes in adult populations, which may include adverse cognitive impacts. 97 The separate or combined effects of other environmental exposures on neurocognitive development are also an important area of investigation. 
